Overactive Bladder News, Treatment Studies | OAB Research Articles

Overactive Bladder (OAB)


NDA Submitted for Vibegron for Overactive Bladder Treatment

Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…

Dementia Tied to Anticholinergic Use

In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.
Patients with refractory OAB most likely represent a minority of the total OAB population.

AUA Updates Overactive Bladder Guideline

Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Training can help reduce salt and fluid intake.

Some Nocturia Cases May Be Eased By Restricting Salt Intake

Decreasing salt intake may benefit patients with nocturia who are heavy salt users, according to a new study published in Neurourology and Urodynamics. In a prospective study, Tomohiro Matsuo, MD, and colleagues from Nagasaki University Graduate School of Biomedical Sciences in Nagasaki, Japan, analyzed changes in lower urinary tract symptoms in 321 patients with nocturia…
Next post in Overactive Bladder (OAB)